Technical Analysis for CLDX - Celldex Therapeutics, Inc.

Grade Last Price % Change Price Change
A 54.39 2.08% 1.11
CLDX closed up 2.08 percent on Friday, September 17, 2021, on 1.77 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical CLDX trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Three Weeks Tight Range Contraction 0.00%
Pocket Pivot Bullish Swing Setup 2.08%
Down 3 Days in a Row Weakness 2.22%
MACD Bearish Signal Line Cross Bearish 0.61%
Hammer Candlestick Bullish 0.61%
Slingshot Bullish Bullish Swing Setup 0.61%
Overbought Stochastic Strength 0.61%
Pocket Pivot Bullish Swing Setup -0.24%
New 52 Week High Strength -0.24%
Older End-of-Day Signals for CLDX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 22 hours ago
Up 1 ATR about 22 hours ago
Possible Pocket Pivot about 22 hours ago
10 DMA Support about 24 hours ago
Rose Above 10 DMA about 24 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Celldex Therapeutics, Inc. Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer. The company also has various earlier stage candidates in clinical development, such as CDX-1135, a molecule that inhibits a part of the immune system called the complement system; CDX-1127, a therapeutic fully human monoclonal antibody for cancer indications that is in Phase I study in patients with selected malignant solid tumors or hematologic cancers; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, which completed Phase I study in healthy subjects; and CDX-1401, an antibody-targeted technology program for cancer indications that completed Phase I study in combination with toll-like receptor agonists poly-ICLC. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Thomas Jefferson University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immunology Clinical Development Solid Tumors Immune System Immunotherapy Treatment Of Cancer Monoclonal Antibody Monoclonal Antibodies Cancer Treatments Breast Cancer Genetics Treatment Of Breast Cancer Ovarian Cancer Blastoma Glioblastoma Cancer Center Antibody Drug Conjugates Brain Tumor Cancer Research Complement System Ovarian Cancers Pivotal Dendritic Cell Advanced Breast Cancer Hematologic Cancers Targeted Immunotherapy Recurrent Glioblastoma Rockefeller University

Is CLDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 56.17
52 Week Low 11.55
Average Volume 886,872
200-Day Moving Average 30.15
50-Day Moving Average 47.21
20-Day Moving Average 52.53
10-Day Moving Average 54.11
Average True Range 2.15
ADX 29.35
+DI 26.41
-DI 17.35
Chandelier Exit (Long, 3 ATRs) 49.73
Chandelier Exit (Short, 3 ATRs) 50.40
Upper Bollinger Bands 56.99
Lower Bollinger Band 48.08
Percent B (%b) 0.71
BandWidth 16.96
MACD Line 2.27
MACD Signal Line 2.62
MACD Histogram -0.3503
Fundamentals Value
Market Cap 2.15 Billion
Num Shares 39.6 Million
EPS -3.74
Price-to-Earnings (P/E) Ratio -14.54
Price-to-Sales 114.73
Price-to-Book 3.74
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.54
Resistance 3 (R3) 59.54 57.82 58.68
Resistance 2 (R2) 57.82 56.51 57.82 58.39
Resistance 1 (R1) 56.11 55.70 55.25 56.11 58.11
Pivot Point 54.39 54.39 53.97 54.39 54.39
Support 1 (S1) 52.68 53.08 51.82 52.68 50.67
Support 2 (S2) 50.96 52.27 50.96 50.39
Support 3 (S3) 49.25 50.96 50.10
Support 4 (S4) 49.25